fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, gi tract, and musculoskeletal system, such as chronic pain. fsd pharma inc. has strategic alliance agreements with scicann therapeutics inc., canntab therapeutics, and solarvest bioenergy inc. the company was founded in 1998 and is headquartered in toronto, canada.
Company profile
Ticker
HUGE, HUGE-CF
Exchange
Website
CEO
Raza Bokhari
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
HUGE stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
25 Apr 24
6-K
Current report (foreign)
22 Apr 24
6-K
Current report (foreign)
17 Apr 24
6-K
FSD Pharma announces Filing of Year-End 2023 Results
15 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
9 Apr 24
20-F
2023 FY
Annual report (foreign)
1 Apr 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Current report (foreign)
5 Mar 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
35.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 368.58 mm |
Total shares | 14.14 mm |
Total puts | 3.00 k |
Total calls | 27.10 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Durkacz Anthony | 13.70 mm | $0.00 |
AdvisorShares Investments | 249.31 k | $286.70 mm |
Renaissance Technologies | 102.60 k | $118.00 k |
Susquehanna International | 57.47 k | $66.09 mm |
Janney Montgomery Scott | 15.00 k | $17.00 k |
Two Sigma Securities | 10.17 k | $11.69 mm |
RY Royal Bank Of Canada | 2.18 k | $2.00 mm |
Advisor | 1.00 k | $1.15 mm |
National Bank of Canada | 716.00 | $816.00 k |
TD Toronto Dominion Bank | 76.00 | $0.00 |
News
FSD Pharma Provides Update From Celly Nu's Partnership With Six+One For Beverage Product unbuzzd
25 Apr 24
FSD Pharma Provides Update On Celly Nu's Anticipated Launch Of unbuzzd; Celly Nu Partners With BevSource
22 Apr 24
'Cannabis Seizures At Checkpoints By U.S.-Mexico Border Frustrates State-Authorized Pot Industry' - Audacy Citing AP
19 Apr 24
'Senator Presses Attorney General Garland On Marijuana Banking Bill's Impact On Criminal Investigations' - Marijuana Moment
17 Apr 24
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
17 Apr 24
Press releases
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)
25 Apr 24
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
17 Apr 24
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
15 Apr 24
FSD Pharma Announces Filing of Year-End 2023 Results
1 Apr 24
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
27 Mar 24